MedPath
Found 59 clinical trials|View Analysis
Sort by:

Pharmacokinetic Study of Tranexamic Acid

Not Applicable
Recruiting
Conditions
Ovarian Neoplasm Epithelial
First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
30
Registration Number
NCT06728670
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Not Applicable
Not yet recruiting
Conditions
Ovarian Neoplasm Epithelial
Fallopian Tube Neoplasms
Ovarian Endometrioid Carcinoma
High-grade Serous Ovarian Carcinoma (HGSOC)
Interventions
Drug: Carboplatin / Paclitaxel Chemotherapy
Other: Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling
First Posted Date
2024-06-20
Last Posted Date
2024-11-27
Lead Sponsor
Swiss GO Trial Group
Target Recruit Count
60
Registration Number
NCT06466382
Locations
🇨🇭

Universitätsspital Basel, Basel, Basel Stadt, Switzerland

The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery

Not Applicable
Completed
Conditions
Ovarian Neoplasm Epithelial
Interventions
Other: acute normovolemic hemodilution (ANH)
Other: acute hypervolemic hemodilution (AHH)
First Posted Date
2023-10-26
Last Posted Date
2023-10-26
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
144
Registration Number
NCT06103214

MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer

Not Applicable
Recruiting
Conditions
Ovarian Neoplasm
Peritoneal Cancer
Ovarian Cancer
Fallopian Tube Cancer
Ovarian Neoplasm Epithelial
Fallopian Tube Neoplasms
Interventions
Procedure: MIRRORS Protocol
Procedure: Standard Open Cytoreductive Surgery
First Posted Date
2023-07-27
Last Posted Date
2023-11-18
Lead Sponsor
Royal Surrey County Hospital NHS Foundation Trust
Target Recruit Count
20
Registration Number
NCT05960630
Locations
🇬🇧

Royal Surrey NHS Foundation Trust, Guildford, Surrey, United Kingdom

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)

Not Applicable
Recruiting
Conditions
Ovarian Neoplasm
Depressive Symptoms
Quality of Life
Interventions
Behavioral: POSTCare Survivorship transition process
First Posted Date
2023-03-02
Last Posted Date
2024-01-12
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
120
Registration Number
NCT05752448
Locations
🇺🇸

UT Southwestern Parkland Health and Hospital System, Dallas, Texas, United States

🇺🇸

Harris Health Smith Clinic, Houston, Texas, United States

🇺🇸

Dan L Duncan Comprehensive Cancer Center at the O'Quinn Medical Tower at Baylor St. Luke's Medical Center, Houston, Texas, United States

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Neoplasm
Interventions
First Posted Date
2023-03-02
Last Posted Date
2023-04-21
Lead Sponsor
Tesaro, Inc.
Target Recruit Count
41
Registration Number
NCT05751629
Locations
🇺🇸

GSK Investigational Site, Oklahoma City, Oklahoma, United States

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Phase 2
Recruiting
Conditions
Fallopian Tube Neoplasms
Ovarian Neoplasm Epithelial
Peritoneal Carcinoma
Ovarian Serous Adenocarcinoma
Ovarian Cancer
Interventions
Biological: Oregovomab
Drug: Paclitaxel
Drug: Carboplatin
Biological: Placebo
First Posted Date
2022-11-04
Last Posted Date
2024-08-20
Lead Sponsor
CanariaBio Inc.
Target Recruit Count
88
Registration Number
NCT05605535
Locations
🇮🇳

King George Hospital, Visakhapatnam, Andhra Pradesh, India

🇮🇳

Omega Hospitals, Visakhapatnam, Andhra Pradesh, India

🇮🇳

Kailash Cancer Hospital and Research Centre, Vadodara, Gujarat, India

and more 13 locations

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Phase 1
Terminated
Conditions
Serous Adenocarcinoma of Ovary
Serous Adenocarcinoma of Primary Peritoneum
Neoplasm, Ovarian
Primary Peritoneal Cavity Cancer
Primary Peritoneal Carcinoma
High Grade Serous Adenocarcinoma
Fallopian Tube Cancer
Adenocarcinoma Ovary
Interventions
First Posted Date
2022-09-14
Last Posted Date
2024-04-24
Lead Sponsor
Avenge Bio, Inc
Target Recruit Count
14
Registration Number
NCT05538624
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

National Cancer Institute, Bethesda, Maryland, United States

🇺🇸

UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States

and more 2 locations

Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs

Not Applicable
Recruiting
Conditions
Neoplasm, Colorectal
Neoplasm, Breast
Neoplasm, Ovarian
Interventions
Device: Individual decision aid (iDA)
First Posted Date
2022-08-23
Last Posted Date
2024-06-28
Lead Sponsor
Karolinska Institutet
Target Recruit Count
220
Registration Number
NCT05512260
Locations
🇸🇪

Karolinska Institutet, Huddinge, Sweden

Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum

Completed
Conditions
Chemotherapy-induced Neutropenia
Chemotherapeutic Toxicity
Ovarian Neoplasm
Chemotherapy Effect
Chemotherapy-induced Nausea and Vomiting
First Posted Date
2022-08-23
Last Posted Date
2022-08-23
Lead Sponsor
Oslo University Hospital
Target Recruit Count
40
Registration Number
NCT05512676
© Copyright 2025. All Rights Reserved by MedPath